Company intelligence / Profile preview

Suturion

Ownership: Private
Employees: ~10
Development stage: Other

Overview

Suturion has developed SutureTOOL™, an innovative medical device designed to standardize and improve the quality and speed of abdominal wall closure after open surgery. Clinical trials have demonstrated that it enables faster, higher-quality closures compared to manual suturing, with the potential to significantly reduce complications such as infections and hernias. The company completed a clinical trial in 2024 and received FDA clearance in early 2025.

Therapeutic areas: GastroenterologyInfectious Diseases
Modalities: Device
Industry: Surgical Medical Devices

Partnerships

European Hernia Society partnershipDistribution agreements with HC21 UKDistribution agreements with Sarabeel Saudi ArabiaDistribution agreements with Optimed Technologies Australia

Beyond the preview

Go deeper on Suturion.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Suturion.

Explore the full profile